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Abstract	  
Background: The management of asymptomatic patients with aortic stenosis (AS) remains 
controversial. Symptoms provoked on exercise testing is a class I indication for aortic valve 
replacement (AVR) but has low specificity. Cardiovascular Magnetic Resonance (CMR) 
measured Myocardial Perfusion Reserve (MPR) is an independent predictor of exercise 
capacity in patients with severe AS and inversely related to symptomatic class. Aims: To 
assess the prognostic value of MPR and exercise testing in asymptomatic patients with 
moderate-severe AS. Method: Multi-centre, prospective, observational study, with blinded 
analysis of CMR data. Patients underwent adenosine stress CMR, symptom-limited exercise 
testing (ETT) and echocardiography and were followed up for 12-30 months. The primary 
outcome was a composite of: typical AS symptoms necessitating referral for AVR, 
cardiovascular death and major adverse cardiovascular events. Results: 174 patients were 
recruited: mean age 66.2±13.34 years, 76% male, peak velocity 3.86±0.56 m/s and aortic 
valve area index 0.57±0.14 cm2/m2. A primary outcome occurred in 47 (27%) patients over a 
median follow-up of 374 (IQR 351-498) days. The mean MPR in those with and without a 
primary outcome was 2.06±0.65 and 2.34±0.70 (p=0.022), while the incidence of a symptom-
limited ETT was 45.7% and 27.0% (p=0.020) respectively. MPR showed moderate 
association with outcome (area under curve (AUC)=0.61 (0.52-0.71, p=0.020), as did 
exercise testing (AUC=0.59 (0.51-0.68, p=0.027), with no significant difference between the 
two. Conclusions: MPR was associated with symptom-onset in initially asymptomatic 
patients with AS, but with moderate accuracy and was not superior to symptom-limited 
exercise testing. ClinicalTrials.gov (NCT01658345).  
Key words: Aortic stenosis, exercise testing, magnetic resonance imaging, myocardial 
perfusion reserve 
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Introduction	  
The optimal management of asymptomatic patients with significant aortic stenosis (AS) 
remains controversial(1). Once symptoms develop there is a dramatic increase in the risk of 
sudden death which may occur before surgical intervention can be undertaken. A key goal of 
decision-making is to reliably identify those who are ‘pre-symptomatic’, so that intervention 
can be offered before the risk of sudden death and operative morbidity increase and the 
benefits from surgical intervention decrease.  Exercise testing is the best-studied risk 
stratification tool in such patients. The recent American Heart Association (AHA)/American 
College of Cardiology (ACC) guidelines state that “patients with symptoms provoked by 
exercise testing should be considered symptomatic” and meet class-I recommendation for 
aortic valve replacement (AVR)(2), a view endorsed by the European Society of Cardiology 
(ESC) guidelines(3). Although patients with a truly negative exercise test have a low 
likelihood of developing symptoms in the short term, its positive predictive value for 
outcome is often poor (54-57%)(4-6).  
 
Several recent studies have utilised the multi-parametric capability of cardiovascular 
magnetic resonance (CMR) imaging to better understand left ventricular (LV) remodeling 
and its consequences in AS. Late gadolinium enhancement (LGE) can detect replacement 
myocardial fibrosis that is associated with poor outcome following AVR(7, 8) and increased 
mortality independent of ejection fraction(9) or pre-operative symptom status(10).  T1 
mapping allows reproducible quantification of myocardial extracellular volume (ECV), a 
measure of diffuse fibrosis in AS(11, 12). We have also shown that myocardial perfusion 
reserve (MPR) measured by CMR was independently associated with exercise capacity and 
inversely with symptomatic class in patients with severe AS(13). These findings suggest that 
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CMR may be a clinically valuable imaging biomarker in stratifying asymptomatic patients 
with AS. 
 
The aim of this study was to compare multi-parametric CMR with exercise testing to predict 
outcome in patients with asymptomatic AS. The primary hypothesis was that MPR would 
have a stronger association with symptom onset and major adverse cardiovascular events 
(MACE) than exercise testing. 
Methods	  
The design and rationale of this study, the PRognostic Importance of MIcrovascular 
Dysfunction in asymptomatic patients with AS (PRIMID AS), has been reported 
previously(14). Briefly, PRIMID AS was a multi-centre, prospective, observational study 
conducted in 10 hospitals in the United Kingdom between April 2012 and November 2014.   
Patients	  
Inclusion criteria were: ages 18 to 85 years, moderate to severe AS (≥2 of: aortic valve area 
<1.5 cm2, peak pressure gradient >36 mmHg or mean pressure gradient >25 mmHg), 
asymptomatic and ability to perform bicycle exercise test. Exclusion criteria were: absolute 
contraindications to CMR, adenosine (severe asthma) or contrast administration (severe renal 
disease); previous cardiac surgery, LV ejection fraction <40%, persistent atrial 
flutter/fibrillation, other severe valve disease, previous heart failure, planned AVR or 
comorbidity limiting life expectancy or precluding AVR.  The study was approved by the 
United Kingdom National Research Ethics Service (11/EM/0410) and all patients gave 
written informed consent prior to any testing. The study was registered on ClinicalTrials.gov 
(NCT01658345).  
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Investigations	  
Detailed phenotyping was performed at one of five regional centres offering a clinical CMR 
service (supplemental table-1).  All investigations were done as research tests and reports 
were not routinely released to the responsible clinicians, so as not to influence patient 
management.  An ECG and comprehensive trans-thoracic echocardiography (TTE), 
according to International guidelines, were performed.  
Exercise	  testing	  
An incremental symptom-limited exercise tolerance test (ETT) was performed on a stationary 
bicycle as previously described(13). Patients were told: ‘Breathlessness is labored or difficult 
breathing characterized by air hunger and an uncomfortable awareness of one’s own 
breathing’.  The ETT was considered symptomatically positive if the patient stopped 
prematurely due to limiting breathlessness or dizziness at <80% of their predicted workload 
or chest pain at any stage (‘strict definition’). Given that the AHA/ACC/ESC(2, 3) guidelines 
consider symptoms at any stage indicative of symptoms, this  ‘conventional definition’ of a 
symptomatically positive test was also considered.  In patients who stopped because of 
fatigue, the ETT was classed as negative or inconclusive if ≥80% or < 80% of the predicted 
workload was achieved respectively. 
CMR	  
A comprehensive stress CMR protocol was used (supplemental figure-1). CMR was 
performed on 3T platforms (supplemental table-1) as previously described(14).  The protocol 
incorporated rest and adenosine stress perfusion, pre and post contrast T1 maps, LV 
function/mass and LGE. 
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Blood	  sampling	  
Patients had venepuncture for haematocrit, electrolytes and storage of plasma for NT-
proBNP, analysed in a single batch at the end of the study, using our in-house non-
competitive assay that employs the quantitative sandwich enzyme immunoassay technique, 
and has excellent correlation with the Roche Elecys assay. 
Image	  Analysis	  
All images were analysed at the core lab in Leicester, blinded to patient details. 
Echocardiography was analysed by an accredited cardiac sonographer, using an Xcelera 
(Philips, Best, The Netherlands) workstation. Quantitative CMR analysis was performed by a 
single observer (AS). Volumetric, T1 mapping and LGE analysis was performed using cvi42 
version-5 (Circle Cardiovascular Imaging, Calgary, Canada) and perfusion analysis, to 
calculate rest and stress myocardial blood flow by model independent deconvolution, was 
performed using Q-mass version-7.1 (Medis, Leiden, Netherlands) as previously 
described(12, 13).  The presence of LGE was agreed by two observers (AS, GPM) and 
quantified using the 5-standard deviation technique(15). Valvulo-arterial impedance (VAI) 
was calculated with stroke volume derived from both TTE and CMR(16). 
Clinical	  follow-­‐up	  
Patients were seen or contacted by telephone at 6 monthly intervals for a minimum of 12 
months or until a pre-defined endpoint was reached, and a maximum of 30 months. A 
primary outcome was defined as a composite of typical AS symptoms necessitating referral 
for AVR, cardiovascular death or MACE (hospitalisation with heart failure, chest pain, 
syncope, arrhythmia).  Referral for AVR in the absence of typical symptoms was considered 
a secondary endpoint. An independent events adjudication committee classified all events as 
a primary or secondary endpoint.  
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Statistical	  Analysis	  
Baseline data was collected using electronic case-record forms, and the blinded imaging data 
were sent to the Robertson Centre for Biostatistics, University of Glasgow, for unblinding 
and statistical analysis. Normally distributed data are expressed as mean±standard deviation.  
Non-parametric data are expressed as median (25%-75% interquartile range). Continuous 
variables were compared between patients with and without an outcome using independent t-
tests or Mann-Whitney tests. The Chi-squared test or Fisher’s exact test were used for 
categorical variables.  Univariate and multivariable determinants of the primary outcome 
were determined using Cox proportional hazards regressions. The multivariable models were 
built using the stepwise selection approach based on adjusted chi-square statistics and consist 
of a series of alternating forward selection and backward elimination steps at p-to-enter and 
p-to-stay levels of 0.05. The following variables were included in the multivariable analyses: 
sex, NT-proBNP, one measure of AS severity, one CMR variable of LV remodeling, MPR 
and  ETT. The stepwise models are included for descriptive purposes to illustrate the fact that 
only a small number of variables may be needed to explain the prognostic value of the 
baseline characteristics. We acknowledge that other models with different subsets of 
variables may have similar prognostic value. Kaplan-Meier curves were generated, using 
optimal cut-off for MPR, for event-free survival and compared using the log-rank test. The 
predictive accuracy of MPR and ETT for the primary outcome was assessed using logistic 
regressions and Receiver Operator Characteristic (ROC) analysis, with calculation of the area 
under the curves (AUC). The AUCs of MPR and ETT were compared using correlated ROC 
analysis. Additional sensitivity analyses were performed in patients with severe AS only.  
The study, with 170 subjects would have 80% power (binomial test) to show that MPR had 
superior overall accuracy (assumed 85%) to ETT, compared to the results of previous studies 
(76%) assuming an annual event rate of 29%(5).  
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Results	  
Clinical	  outcomes	  
A total of 174 patients were recruited (figure-1, table-1) of whom 123 (71%) met at least one 
criterion for severe AS(3). During a median follow-up of 374 (IQR 351-498) days the 
primary outcome occurred in 47 (27.0%) patients: all but one developed symptoms and 2 
died. A secondary outcome occurred in 60 (34.5%) patients with 13 having AVR whilst 
asymptomatic. Despite constituting only 23.6% of the participants, females accounted for 
38.3% of those who developed a primary outcome. These patients also had more severe 
disease, with higher gradients and lower valve area, higher NT-proBNP, lower haemoglobin 
and eGFR.  
ETT	  
There were no medical complications during exercise testing, which was performed by all but 
two patients. The reasons for stopping were: fatigue/discomfort (114), dyspnoea (n=51), 
chest pain (n=4), bigeminy (n=2) and hypertension (n=1). Thirty per cent of the patients had 
an inconclusive exercise test. Patients with a primary outcome had a greater proportion of 
symptomatically positive tests (using both definition) (table-2).  
CMR	  
CMR was completed in all participants without complications. MPR was not analysable in 
nine patients. Patients with a primary outcome displayed lower stroke volumes, with similar 
indexed LV volumes and mass (table-2). Global MPR was significantly lower in the outcome 
group (2.06 ± 0.65 vs. 2.34 ± 0.70, p = 0.022). There was no significant difference in the 
frequency and quantity of scarring assessed with LGE.  Fifty-three patients did not have T1 
mapping performed due to unavailability of the pulse sequence at one site for part of the 
study.  ECV was not significantly higher in those with an outcome. 
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Comparison	  of	  MPR	  and	  ETT	  
ROC curves for MPR and ETT for the primary outcome are shown in figure-2. The negative 
and inconclusive ETTs were grouped together and compared to positive ETTs. The AUC for 
MPR was statistically significant: 0.61, (0.52-0.71), p=0.020 with an optimal cut-off of 2.10. 
The AUC for ETT were: 0.59 (0.51-0.68), p=0.027 (‘conventional’ definition) and 0.56 
(0.50-0.62), p=0.070 (‘strict’ definition). Event-free survival was significantly lower in those 
with low MPR and a positive ETT (figure-3). The specificity, sensitivity, positive predictive 
value (PPV) and negative predictive value (NPV) are shown in table-3. Both MPR and 
positive ETT had high NPV, but low PPV. The strict definition had a very high specificity 
but very low sensitivity. Similar results were seen for the 123 patients with severe AS. 
(supplemental table-3). There was no significant difference between the AUCs of MPR and 
ETT using correlated ROC analysis (0.05(-0.06-0.17, p=0.345) for strict definition and 
0.03(-0.11-0.17, p=0.677) for conventional definition). 
Univariate	  associations	  with	  primary	  outcome	  
Both symptom-limited ETT and low MPR were univariate predictors of the primary outcome 
after adjusting for sex (table-4). Increasing AS severity, increased mass/volume ratio, VAI, 
NT-proBNP and resting LV rate pressure product were also associated with the primary 
outcome.  
Multivariable	  associations	  with	  primary	  and	  secondary	  outcomes	  
The following variables were included in the stepwise analysis model: sex, NT-proBNP, 
aortic valve area index (AVAI), MPR, LV mass/volume ratio and positive ETT. Gender and 
AVAI remained independent predictors of outcome, with positive ETT also being a predictor 
using the strict definition only, and NT-proBNP using conventional definition (table-4). The 
results did not change when AS severity was entered into the model instead of AVAI, other 
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than NT-proBNP was also independently associated with outcome using the strict definition 
on ETT.  
In patients with severe AS only, AVAI remained an independent predictor, with the addition 
of gender and positive ETT for strict definition only (supplemental table-4). For the 
secondary outcome, AVAI, MPR and symptomatically positive ETT (strict and conventional 
definitions) were independent predictors of the combined endpoint of all AVR/symptoms and 
MACE (supplemental table-2).  
Discussion	  
A number of studies have linked LV remodeling, and particularly myocardial fibrosis, with 
adverse outcome in AS. This is the first prospective study to explore the hypothesis that 
CMR could predict the development of symptoms in asymptomatic patients with AS. MPR is 
an independent predictor of exercise capacity and inversely associated with NYHA class in 
patients with severe AS undergoing AVR(13). In this study we have confirmed that low MPR 
in initially asymptomatic patients is also associated with the development of symptoms in the 
medium term. However, the accuracy of MPR to predict outcome was moderate at best and, 
contrary to our primary hypothesis, not significantly better than exercise testing.  This is also 
the largest cohort of patients with asymptomatic moderate-severe AS to date to have 
undergone both exercise testing and CMR. The primary endpoint occurred in 27% of patients 
and the secondary endpoint in 35%, and is comparable to that seen in previous reports(5, 6).  
Exercise	  testing	  
It may be surprising that exercise testing to identify ‘pre-symptomatic patients’ performed 
poorly in this study, given the class-I indication for surgery in the major International 
guidelines. It is worth noting that the 2014 AHA/ACC guidelines re-classified symptoms on 
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exercise testing from a class IIb to a class I indication for AVR, which was after the 
commencement of our study and when ETT was not widely adopted in our institutions.  
However, our results are largely consistent with the published literature. A normal exercise 
test has a high negative predictive accuracy (ranging from 0.86-1.00 in previous studies 
compared to 0.79 in ours)(4, 6, 17), suggesting that these patients can be safely managed 
conservatively. However, although patients who develop symptoms on exercise testing are at 
higher risk of developing spontaneous symptoms or experiencing MACE, the specificity of a 
positive test is low (0.60-0.78 in previous studies compared to 0.73 in ours)(4, 5). In this 
study, only 20 of 55 patients who had a positive test using a conventional definition 
developed spontaneous symptoms during follow-up. The results were consistent in a 
sensitivity analysis of patients with severe AS as well (specificity 0.71). If current guidelines 
were followed, many patients may be sent for early surgery unnecessarily, as the majority of 
patients with a positive test did not develop spontaneous symptoms in the medium term. This 
calls into question the recommendation of exercise-induced symptoms as a class-I indication 
for AVR(2, 3), which is not based on data from randomised controlled trials. Previous studies 
looking at the prognostic value of exercise testing in AS have generally been single-centre 
studies, with relatively small numbers of patients (n=30-160)(4, 6, 16, 17).  Another 
disadvantage of ETT is the high proportion of patients with inconclusive results (30%), 
despite restricting inclusion to those who can exercise, which reflects the subjective nature 
and limitation of the test in the real world. 
 
As previously demonstrated(6), echocardiographic measures of severity are important 
predictors of outcome but with wide overlap in those who do and do not develop symptoms.  
Only one other study has identified female gender as increasing risk of symptoms(18). 
Female patients may have a different remodeling process, as suggested by lower cardiac 
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volumes and more concentric LV geometry than men(19). This may suggest a need for 
gender-specific cut-offs for definition of severity. Female patients also tend to perform less 
well on exercise testing(20), and may therefore be more likely to be labelled as having an 
inconclusive test, and not identified as high risk until a later stage. 
CMR	  predictors	  of	  outcome	  
This is the first CMR study assessing the prognostic value of MPR, LGE and ECV in 
asymptomatic patients with AS. MPR was significantly lower in the primary outcome group, 
a univariate predictor of outcome, as well as there being significant survival difference in 
those with a low and high MPR on Kaplen-Meier analysis. ROC analysis also demonstrated 
statistically significant AUC for MPR to predict the primary outcome. Two previous studies 
have shown TTE measured coronary flow reserve (CFR) to be independently associated with 
mortality in patients with moderate to severe AS, though the numbers were small with 
significant other limitations(20, 21).  
LGE and ECV in this study were not associated with the primary outcome. Although LGE 
has been shown to predict poor outcome, this has been almost exclusively in patients with 
severe AS who have undergone AVR(7, 8). In that context LGE represents replacement 
fibrosis and is likely indicative of irreversible LV dysfunction. There has been intense 
interest in quantification of ECV, a surrogate of diffuse interstitial fibrosis, and its 
relationship to clinical outcomes in a range of cardiac conditions, especially AS(11). We saw 
only a very small difference in ECV (1%) between those with and without an outcome and 
have previously shown that ECV is not increased in asymptomatic patients with AS, 
compared to age and sex-matched controls(12). The normal range of ECV is in the order of 
25%, and there is very wide overlap between patients and healthy controls and therefore it is 
likely to be insensitive to small increases in interstitial fibrosis. So, although ECV may detect 
differences in populations, it is unlikely to be of clinical value in individual patients unless 
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they have extreme values, such as in amyloidosis(22). The lack of association of LV mass 
and volumes with outcome is again likely to be related to the high event rate in female 
patients, who have smaller hearts even when indexed to body size. 
Strengths	  
This was a prospective, multicentre study, and although observational, was run from outset to 
the same standards as a randomised controlled trial.  The CMR and ETT results were blinded 
to the clinicians, imaging tests were analysed in a core lab, and there was independent event 
adjudication and statistical analysis.  We also recruited a well-described population who were 
regarded as low risk (in whom prophylactic AVR may be offered) and were prepared to have 
surgery should symptoms develop. Finally, the primary endpoint was carefully defined and 
excluded those being referred for AVR prior to the onset of spontaneous symptoms, which is 
a soft endpoint.  
Limitations	  
Although this study was large for its kind, the number of clinical events was relatively small 
and this limits the number of variables that could be entered into the multivariable model. 
The inclusion of patients with moderate disease may be criticised, however, these patients do 
have high event rates and the results of the study were consistent when only the 123 patients 
with severe AS were analysed. There was also missing data (T1 mapping) due to technical 
problems during the study, but his did not affect the primary outcome analysis. Finally, 
although there was a statistically significant difference in MPR between those with and 
without an outcome, the difference was small with large overlap between the two groups, 
somewhat limiting its clinical use. 
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Conclusions	  
CMR measured MPR and symptom-limited exercise testing are associated with clinical 
outcome in initially asymptomatic patients with moderate-severe AS. However, predictive 
accuracy is moderate at best and MPR is not superior to symptom-limited exercise testing. 
Further refinement of risk-stratification is required in asymptomatic AS. 
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Legends	  
 
Figure 1. Recruitment flowchart 
 
Figure 2. ROC curves for MPR and symptom-limited ETT (a. conventional definition, 
b. strict definition) for predicting the primary outcome  
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Figure 3. Kaplan-Meier curves for event-free survival for those a.) above and below 
MPR cut-point of 2.098, b.) symptom-limited ETT (conventional definition) and c.) 
symptom-limited ETT (strict definition) 
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Table 1. Demographic and echocardiography data 	   All	  patients	  (n=174)	   Primary	  outcome	  (n=47)	   No	  primary	  outcome	  (n=127)	   p-­‐value	  	  
Demographic	  data	  
Age	  (years)	   66.2	  ±	  13.34	   68.7	  ±	  11.54	   65.3	  ±	  13.89	   0.144	  
Male	  (n	  (%))	   133	  (76.4)	   29	  (61.7)	   104	  (81.9)	   0.005*	  
BSA	  (m2)	   2.0	  ±	  0.21	   1.9	  ±	  0.18	   2.0	  ±	  0.21	   0.034*	  
Resting	  HR	  (bpm)	   70.3	  ±	  11.43	   70.1	  ±	  13.80	   70.4	  ±	  10.47	   0.918	  
Resting	  SBP	  (mmHg)	   146.9	  ±	  21.09	   147.3	  ±	  22.80	   146.8	  ±	  20.51	   0.886	  
Resting	  DBP	  (mmHg)	   77.2	  ±	  10.65	   75.2	  ±	  10.80	   77.9	  ±	  10.54	   0.148	  
Diabetes	  (n	  (%))	   25	  (14.4)	   8	  (17.0)	   17	  (13.4)	   0.544	  
Hypertension	  (n	  (%))	   93	  (53.4)	   25	  (53.2)	   68	  (53.5)	   0.967	  
Hyperlipidaemia	  (n	  (%))	   92	  (52.9)	   22	  (46.8)	   70	  (55.1)	   0.577	  
ACE-­‐I/ARB	  (n	  (%))	   77	  (44.3)	   18	  (38.3)	   59	  (46.5)	   0.336	  
Beta-­‐blocker	  (n	  (%))	   54	  (31.0)	   19	  (40.4)	   35	  (27.6)	   0.103	  
Statin	   105	  (60.3)	   27	  (57.4)	   78	  (61.4)	   0.635	  
NT-­‐proBNP	  (pmol/L)	   56.51	  (19.22,	  152.52)	   129.97	  (36.86,	  254.31)	   48.69	  (17.18,	  124.47)	   0.008*	  
Hb	  (g/dL)	   14.2	  ±	  1.24	   13.9	  ±	  1.14	   14.4	  ±	  1.25	   0.016*	  
eGFR	  (ml/min)	   88	  ±	  28.6	   79	  ±	  19.2	   91	  ±	  30.8	   0.004*	  
Echocardiography	  data	  
AV	  Vmax	  (m/s)	   3.86	  ±	  0.56	   4.13	  ±	  0.61	   3.76	  ±	  0.51	   <0.001*	  
MPG	  (mmHg)	   35.4	  ±	  12.49	   41.5	  ±	  14.15	   33.1	  ±	  11.04	   <0.001*	  
AVAI	  (cm2/m2)	   0.57	  ±	  0.14	   0.51	  ±	  0.15	   0.59	  ±	  0.13	   0.001*	  
E/A	   0.88	  ±	  0.29	   0.85	  ±	  0.30	   0.89	  ±	  0.28	   0.388	  
Septal	  E/e’	   12.28	  ±	  4.86	   13.23	  ±	  5.61	   11.92	  ±	  4.52	   0.125	  
Lateral	  E/e’	   9.88	  ±	  3.72	   10.59	  ±	  3.44	   9.62	  ±	  3.80	   0.137	  
VAI	  (Echo)	  
(mmHg/ml/m2)	  
3.96	  ±	  1.06	   4.18	  ±	  1.18	   3.88	  ±	  1.00	   0.096	  
 
Abbreviations: BSA=body surface area, HR=heart rate, SBP/DBP=systolic/diastolic blood pressure, ACE-
I=angiotensin converting enzyme inhibitor, ARB=angiotensin II receptor blocker, NT-proBNP=N terminal 
brain natriuretic peptide, Hb=haemoglobin, eGFR=estimated glomerular filtration rate, AV Vmax=peak aortic 
jet velocity, MPG=mean pressure gradient, AVAI=aortic valve area indexed to BSA, VAI=valvulo-arterial 
impedance. (* p<0.05 between outcome and no outcome groups) 
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Table 2. Exercise test and cardiovascular magnetic resonance imaging data 	   Primary	  
outcome	  (n=47)	   No	  primary	  outcome	  (n=127)	   p-­‐value	  	  
ETT	  data	  
Exercise	  duration	  (min)	   8.45	  ±	  2.55	   8.51	  ±	  1.79	   0.892	  
Peak	  workload	  (W)	   96	  ±	  33.7	   115	  ±	  41.2	   0.006*	  
%	  predicted	  workload	  (%)	   85.4	  ±	  25.6	   86.7	  ±	  28.2	   0.775	  
%	  predicted	  HR	  (%)	   87.4	  ±	  11.9	   86.5	  ±	  11.8	   0.657	  
Rise	  in	  SBP	  (mmHg)	   37	  ±	  24.8	   43	  ±	  21.0	   0.098	  
Positive	  ETT	  (strict)	  (%)	   19.6	   7.9	   0.031*	  
Positive	  ETT	  (conventional)	  (%)	   45.7	   27.0	   0.020*	  
CMR	  data	  
LVEDVI	  (ml/m2)	   84.47	  ±	  15.38	   88.73	  ±	  19.16	   0.173	  
LVESVI	  (ml/m2)	   36.15	  ±	  9.20	   39.07	  ±	  11.07	   0.109	  
LVSV	  (ml)	   92	  ±	  16.2	   99	  ±	  25.1	   0.033*	  
LVSVI	  (ml/m2)	   48.29	  ±	  7.79	   49.68	  ±	  9.82	   0.383	  
LVEF	  (%)	   57.5	  ±	  4.60	   56.4	  ±	  5.05	   0.167	  
LVMI	  (g/m2)	   57.14	  ±	  12.15	   57.90	  ±	  14.46	   0.750	  
LV	  mass/volume	  (g/ml)	   0.68	  ±	  0.13	   0.66	  ±	  0.10	   0.146	  
LAVI	  (ml/m2)	   57.31	  ±	  17.33	   54.05	  ±	  13.61	   0.251	  
VAI	  (MRI)	  (mmHg/ml/m2)	   4.00	  ±	  0.80	   3.74	  ±	  0.82	   0.065	  
Global	  MPR	   2.06	  ±	  0.65	   2.34	  ±	  0.70	   0.022*	  
Global	  stress	  MBF	  (ml/min/g)	   2.05	  ±	  0.64	   2.20	  ±	  0.72	   0.216	  
Global	  rest	  MBF	  (ml/min/g)	   1.05	  ±	  0.36	   0.96	  ±	  0.22	   0.119	  
LGE	  present	  (n,%)	   24	  (51.1)	   58	  (45.7)	   0.527	  
%	  LGE	  (%)	   4.4	  ±	  3.19	   4.2	  ±	  3.96	   0.683	  
Native	  T1	  (ms)	   1114.3	  ±	  61.13	   1139.4	  ±	  71.85	   0.070	  
ECV	  (%)	   25.35	  ±	  2.53	   24.60	  ±	  2.37	   0.132	  
 
Abbreviations: ETT=exercise tolerance test, LVEDVI=left ventricular end-diastolic volume indexed to BSA, 
LVESVI=left ventricular end systolic volume indexed to BSA, LVSI=left ventricular stroke volume indexed to 
BSA, LVEF=left ventricular ejection fraction, LVMI=left ventricular mass indexed to BSA, LAVI=left atrial 
volume indexed to BSA, VAI=valvulo-arterial impedance, MPR=myocardial perfusion reserve, 
MBF=myocardial blood flow, LGE=late gadolinium enhancement, ECV=extracellular volume fraction. (* 
p<0.05) 
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Table 3. Sensitivity, specificity, positive and negative predictive value of MPR and 
exercise testing for predicting the primary outcome 
 
Parameter	   Sensitivity	  
(95%	  CI)	  
Specificity	  
(95%	  CI)	  
PPV	  
(95%	  CI)	  
NPV	  
(95%	  CI)	  
MPR	   0.59	  (0.43,	  0.73)	   0.63	  (0.54,	  0.72)	   0.38	  (0.27,	  0.50)	   0.80	  (0.70,	  0.87)	  
Positive	  ETT	  
(strict)	  
0.20	  (0.09,	  0.34)	   0.92	  (0.86,	  0.96)	   0.47	  (0.25,	  0.71)	   0.76	  (0.68,	  0.82)	  
Positive	  ETT	  
(conventional)	  
0.46	  (0.31,	  0.60)	   0.73	  (0.64,	  0.81)	   0.38	  (0.25,	  0.52)	   0.79	  (0.70,	  0.86)	  
 
Abbreviations: PPV=positive predictive value, NPV=negative predictive value, MPR=myocardial perfusion 
reserve, ETT=exercise tolerance test. Sample size for MPR=165, for ETT=172.  
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Table 4. Univariate (adjusted for sex) and multivariable associations of primary 
outcome (model 1: strict definition ETT, model 2: conventional definition ETT) 
Variable	   Univariate	   Multivariable-­‐model	  1	   Multivariable-­‐model	  2	  
	   HR	  (95%	  CI)	   p-­‐value	   HR	  (95%	  CI)	   p-­‐value	   HR	  (95%	  CI)	   p-­‐value	  
Gender	  (M	  vs.	  F)	   0.47	  (0.26	  -­‐	  0.84)	   0.011	   0.42	  (0.22	  -­‐	  0.79)	   0.008	   0.54	  (0.29	  -­‐	  0.99)	   0.045	  
AV	  Vmax	   3.25	  (1.99	  -­‐	  5.31)	   <0.001	   	   	   	   	  
MPG	   1.05	  (1.03	  -­‐	  1.07)	   <0.001	   	   	   	   	  
AVAI	   0.63	  (0.50	  -­‐	  0.80)	   <0.001	   0.61	  (0.47	  -­‐	  0.80)	   <0.001	   0.60	  (0.47	  -­‐	  0.77)	   <0.001	  
VAI	  (Echo)	   1.30	  (1.04	  -­‐	  1.63)	   0.024	   	   	   	   	  
VAI	  (CMR)	   1.42	  (1.02	  -­‐	  1.98)	   0.035	   	   	   	   	  
LV	  mass	  /	  Volume	   1.32	  (1.04	  -­‐	  1.68)	   0.023	   	   	   	   	  
MPR	   0.62	  (0.39	  -­‐	  0.97)	   0.035	   	   	   	   	  
Log	  (NT-­‐proBNP)	   1.28	  (1.05	  -­‐	  1.56)	   0.015	   	   	   1.22	  (1.00	  -­‐	  1.48)	   0.048	  
Positive	  ETT	  (strict)	   4.17	  (1.92	  -­‐	  9.05)	   <0.001	   3.41	  (1.55	  -­‐	  7.50)	   0.002	   	   	  
Positive	  ETT	  
(conventional)	  
1.90	  (1.06	  -­‐	  3.42)	   0.032	   	   	   	   	  
Resting	  LVRPP	   2.89	  (1.14	  -­‐	  7.37)	   0.026	   	   	   	   	  
 
Abbreviations: As tables 1 and 2 
